- Home
- ECBK vs LENZ Comparison
ECBK vs LENZ Comparison
Compare ECBK & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECBK | LENZ |
|---|---|---|
| Founded | 1919 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.5M | 142.0M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ECBK | LENZ |
|---|---|---|
| Price | $20.62 | $4.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $44.00 |
| AVG Volume (30 Days) | 6.4K | ★ 624.3K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.83 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | $598,000.00 | ★ $19,088,000.00 |
| Revenue This Year | N/A | $50.42 |
| Revenue Next Year | N/A | $197.16 |
| P/E Ratio | $26.95 | ★ N/A |
| Revenue Growth | ★ 3.64 | N/A |
| 52 Week Low | $14.83 | $4.01 |
| 52 Week High | $21.53 | $50.19 |
Technical Indicators
Market Signals| Indicator | ECBK | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 47.57 | 32.77 |
| Support Level | $20.12 | N/A |
| Resistance Level | $20.79 | $6.11 |
| Average True Range (ATR) | 0.53 | 0.32 |
| MACD | -0.04 | -0.11 |
| Stochastic Oscillator | 28.79 | 4.06 |
Price Performance
Historical ComparisonAbout ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company. The firm, through its subsidiary, engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, multifamily real estate loans, construction and land loans, and home equity lines of credit.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.